ERYTECH Announces Fast Take-off of Its Phase IIb Study in Acute Myeloid Leukemia 100% Of French Sites Authorized to Participate in the Study, More Than 50% of Which Are Open for Patient Enrollment Already 10% of Patients Enrolled in the Study Opening of Additional European Centers Forthcoming to
ERYTECH provides financial update for Q1 2013 RELEASE 03 JUN 2013 19:17 CET Regulatory News: ERYTECH, (Paris:ERYP) (NYSE Euronext Paris : FR0011471135 - ERYP) a French biopharmaceutical company that develops innovative
ERYTECH’s IPO a remarkable success, raising €17.7 million The company’s capital increased by nearly €28 million through: IPO (OPO & GP) raising €16.7 million Subscription in compensation for debts of nearly €1 million Conversion of convertible bonds for a total of €10 million, including
ERYTECH Announces its IPO on NYSE Euronext Paris Regulated Market Regulatory News: This document may not be published, distributed or circulated, either directly or indirectly, in the United States, Canada, Australia, Italy or Japan ERYTECH (Paris:ERYP), a French biopharmaceutical company that
ERYTECH Pharma Receives FDA IND Clearance to Initiate a Clinical Study in Acute Lymphoblastic Leukemia in the U.S. April 03, 2013 07:58 AM Eastern Daylight Time LYON, France & PHILADELPHIA--( BUSINESS WIRE )-- ERYTECH Pharma SA announced today that it has received clearance of its Investigational
LYON, France--( BUSINESS WIRE )--ERYTECH Pharma, a late stage biopharmaceuticals company focused on orphan oncology and rare diseases, announced today that it has entered into a definitive agreement with Orphan Europe, part of the Recordati Group, granting Orphan Europe exclusive rights for the
ERYTECH Pharma announces the oral presentation of very demonstrative results regarding its technology to Induce specific immune tolerance by antigen loaded erythrocytes. Therapeutic proteins are often immunogenic, inducing anaphylactic reactions and/or specific immunoglobulins.
ERYTECH Pharma Announces the Oral Presentation of Positive Phase II Clinical Trial Results in Acute Lymphoblastic Leukemia June 17, 2012 05:00 AM Eastern Daylight Time LYON, France--( BUSINESS WIRE )--The oral presentation will be held on June 17th 2012 by Prof. Dr.
ERYTECH Pharma’s Sickle Cell Treatment Receives Positive Opinion for Orphan Drug Designation from the European Medicines Agency June 13, 2012 08:00 AM Eastern Daylight Time LYON, France--( BUSINESS WIRE )-- ERYTECH Pharma, a late stage biopharmaceuticals company focused on orphan oncology and
ERYTECH Pharma Receives € 7 Million from OSEO to Lead the TEDAC Personalized Medicine Project in Cancer Financing of € 6.95 million through grants and redeemable advances from the French public organization OSEO Leader of the collaborative project that aims to create major innovations within a
